Hadron therapy, which relies on beams of charged particles including protons and heavier ions such as carbon, is expected to increase cancer cure rates because it can be used to treat larger tumors or those resistant to conventional radiotherapy.
Patients with a group of cancers known as advanced systemic mastocytosis have few treatment options. A drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
